These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31019892)

  • 1. Detection of
    Lee J; Franovic A; Shiotsu Y; Kim ST; Kim KM; Banks KC; Raymond VM; Lanman RB
    Front Oncol; 2019; 9():212. PubMed ID: 31019892
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
    Kim ST; Banks KC; Pectasides E; Kim SY; Kim K; Lanman RB; Talasaz A; An J; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Park SH; Park JO; Park YS; Lim HY; Kim NKD; Park W; Lee H; Bass AJ; Kim K; Kang WK; Lee J
    Ann Oncol; 2018 Apr; 29(4):1037-1048. PubMed ID: 29409051
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Barzi A; Weipert CM; Espenschied CR; Raymond VM; Wang-Gillam A; Nezami MA; Gordon EJ; Mahadevan D; Mody K
    Front Oncol; 2024; 14():1339302. PubMed ID: 38406801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma HER2 (
    Siravegna G; Sartore-Bianchi A; Nagy RJ; Raghav K; Odegaard JI; Lanman RB; Trusolino L; Marsoni S; Siena S; Bardelli A
    Clin Cancer Res; 2019 May; 25(10):3046-3053. PubMed ID: 30808777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
    Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
    Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 7. Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.
    Page K; Guttery DS; Fernandez-Garcia D; Hills A; Hastings RK; Luo J; Goddard K; Shahin V; Woodley-Barker L; Rosales BM; Coombes RC; Stebbing J; Shaw JA
    Clin Chem; 2017 Feb; 63(2):532-541. PubMed ID: 27940449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.
    Shah AN; Sunderraj A; Finkelman B; See SH; Davis AA; Gerratana L; Wehbe F; Katam N; Mahalingam D; Gradishar WJ; Behdad A; Blanco L; Cristofanilli M
    Oncotarget; 2022; 13():273-280. PubMed ID: 35126865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal
    Kumaki Y; Olsen S; Suenaga M; Nakagawa T; Uetake H; Ikeda S
    Curr Oncol; 2021 Sep; 28(5):3717-3728. PubMed ID: 34677235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
    Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
    Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Putative Clinical Potential of
    Boldrin E; Mazza M; Piano MA; Alfieri R; Montagner IM; Magni G; Scaini MC; Vassallo L; Rosato A; Pilati P; Scapinello A; Curtarello M
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
    Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
    Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer.
    Chan RH; Lin PC; Chen SH; Lin SC; Chen PC; Lin BW; Shen MR; Yeh YM
    Front Oncol; 2021; 11():589673. PubMed ID: 33816227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Landscape of
    Wang H; Miao J; Wen Y; Xia X; Chen Y; Huang M; Chen S; Zhao Z; Zhang Y; Chen C; Zhu X
    Pathol Oncol Res; 2022; 28():1610360. PubMed ID: 35911441
    [No Abstract]   [Full Text] [Related]  

  • 15. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer.
    He J; Hu X; Chen L; Liu Q; Jiang Y
    Front Genet; 2022; 13():850290. PubMed ID: 35646096
    [No Abstract]   [Full Text] [Related]  

  • 17. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
    Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
    J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
    Cenaj O; Ligon AH; Hornick JL; Sholl LM
    Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.